Loading...
•
Apr 25
Medtronic Q4 2025 Earnings Report
Medtronic posted a strong Q4 with solid revenue and earnings growth, supported by double-digit expansion in its Cardiac Ablation and Diabetes businesses.
Key Takeaways
Medtronic delivered a robust Q4 FY25 performance with nearly $9 billion in revenue and strong growth in key franchises such as Cardiac Ablation and Diabetes. The company also announced a strategic plan to spin off its Diabetes business.
Revenue reached $8.93 billion, up from $8.59 billion last year
GAAP EPS surged to $0.82, and Non-GAAP EPS rose to $1.62
Net Income climbed to $1.06 billion, reflecting 62% growth
Medtronic announced intent to spin off its Diabetes business
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Revenue by Segment
Cardiac Rhythm & HF Revenue
CapyFin.comStructural Heart & Aortic Revenue
CapyFin.comCoronary & Peripheral Vascular Revenue
CapyFin.comCranial & Spinal Technologies Revenue
CapyFin.comSpecialty Therapies Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comSurgical & Endoscopy Revenue
CapyFin.comAcute Care & Monitoring Revenue
CapyFin.comDiabetes Revenue
CapyFin.comOther Segment Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Medtronic expects FY26 organic revenue growth of approximately 5%, and non-GAAP EPS between $5.50 and $5.60 depending on tariff impacts.
Positive Outlook
- 5% organic revenue growth expected in FY26
- Non-GAAP EPS projected at $5.50 to $5.60
- Continued momentum in key growth drivers
- Leverage on operating profit anticipated
- Robust mitigation plans for potential tariffs
Challenges Ahead
- Tariff risks could impact lower EPS guidance range
- Rising interest expenses forecasted
- Higher tax expenses expected
- Continued restructuring and separation costs
- Global macro uncertainties may weigh on margins
Revenue & Expenses
Visualization of income flow from segment revenue to net income